Lynk Pharmaceuticals Co., Ltd. | 浙ICP备19010130号-2 | Powered by www.300.cn | Manager
CONTACT US
website
291 Fucheng Road, Bldg 5-402, Jianggan, Hangzhou,
Zhejiang 310018, China
Lynk Pharmaceuticals and Simcere announced Strategic Commercialization Partnership upon novel JAK1 inhibitor LNK01001

Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Study of LNK01001 in Patients with Atopic Dermatitis

Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Study of LNK01001 in Patients with Ankylosing Spondylitis

Lynk Pharmaceuticals Announced First Patient Dosed in Phase II Clinical Study of LNK01001

Lynk Pharmaceuticals announced the completion of Series B financing of $50 million

上一页
1
2
3
下一页